InvestorsHub Logo
Followers 3
Posts 292
Boards Moderated 0
Alias Born 12/21/2022

Re: None

Sunday, 03/12/2023 10:09:47 AM

Sunday, March 12, 2023 10:09:47 AM

Post# of 569
According to most recent corporate presentation, it should occur in Q1 2023:
EOP1 Meeting with FDA to establish response rates for accelerated approval as monotherapy for R/R AML/ Prior FLT3i failure and
to set stage for triplet trials.
Since APTO earning call is on Mar 23, 2023, most likely they will tell us about the outcome of this meeting.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News